|
gptkbp:instanceOf
|
gptkb:recreational_drug
gptkb:synthetic_cathinone
gptkb:chemical_compound
|
|
gptkbp:actsOn
|
serotonin-norepinephrine-dopamine reuptake inhibitor
releasing agent
|
|
gptkbp:appearance
|
white to off-white crystalline powder
|
|
gptkbp:CASNumber
|
186028-79-5
|
|
gptkbp:category
|
gptkb:recreational_drug
gptkb:phenethylamine_derivative
substituted cathinone
|
|
gptkbp:discoveredBy
|
gptkb:Jacob_Peyton
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:firstSynthesized
|
1996
|
|
gptkbp:halfLife
|
approximately 6 hours
|
|
gptkbp:hasInChIKey
|
InChI=1S/C11H13NO3/c1-7(12-2)6-8-3-4-9-10(5-8)15-7-11(13)14-9/h3-5,7,12H,6H2,1-2H3
|
|
gptkbp:hasMolecularFormula
|
C11H13NO3
|
|
gptkbp:hasSMILES
|
CC(CC1=CC2=C(C=C1)OCO2)NC
|
|
gptkbp:IUPACName
|
1-(1,3-benzodioxol-5-yl)-2-(methylamino)propan-1-one
|
|
gptkbp:legal_status_(Canada)
|
gptkb:Schedule_III
|
|
gptkbp:legal_status_(UK)
|
Class B drug
|
|
gptkbp:legalStatus
|
Schedule I controlled substance
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
207.23 g/mol
|
|
gptkbp:otherName
|
gptkb:3,4-methylenedioxy-N-methylcathinone
gptkb:bk-MDMA
|
|
gptkbp:pharmacological_effect
|
gptkb:stimulant
gptkb:entactogen
empathogen
|
|
gptkbp:PubChem_CID
|
2104677
21106398
45357845
|
|
gptkbp:relatedTo
|
gptkb:MDMA
gptkb:mephedrone
|
|
gptkbp:riskFactor
|
potential for abuse
adverse effects include anxiety, agitation, tachycardia
|
|
gptkbp:routeOfAdministration
|
injection
oral
insufflation
|
|
gptkbp:UNII
|
4U6Z3848E6
|
|
gptkbp:usedFor
|
gptkb:recreational_drug
|
|
gptkbp:bfsParent
|
gptkb:BAS_(rapper)
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Methylone
|